Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 6 results
Author
Title
[
Type
]
Year
Filters:
Keyword
is
Remission Induction
[Clear All Filters]
Journal Article
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
Panaccione R
,
Danese S
,
Sandborn WJ
,
O'Brien CD
,
Zhou Y
,
Zhang H
,
Adedokun OJ
,
Tikhonov I
,
Targan S
,
Abreu MT
et al.
. 2020.
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
.
Aliment Pharmacol Ther. 52(11-12):1658-1675.
Jacob V
,
Crawford C
,
Cohen-Mekelburg S
,
Viladomiu M
,
Putzel GG
,
Schneider Y
,
Chabouni F
,
OʼNeil S
,
Bosworth B
,
Woo V
et al.
. 2017.
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.
.
Inflamm Bowel Dis. 23(6):903-911.
Faleck DM
,
Winters A
,
Chablaney S
,
Shashi P
,
Meserve J
,
Weiss A
,
Aniwan S
,
Koliani-Pace JL
,
Kochhar G
,
Boland BS
et al.
. 2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Scherl EJ
. 2002.
Irritable-inflammatory bowel disease: recognizing a new overlap syndrome and an enigma wrapped inside a puzzle.
.
Inflamm Bowel Dis. 8(5):373-4.
Yang E
,
Panaccione N
,
Whitmire N
,
Dulai PS
,
Casteele NVande
,
Singh S
,
Boland BS
,
Collins A
,
Sandborn WJ
,
Panaccione R
et al.
. 2020.
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
.
Aliment Pharmacol Ther. 51(11):1031-1038.